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Despite 3 decades of progress made in the manage-
ment of bacterial and viral infections in immunosup-
pressed allogeneic stem cell transplant recipients,
major treatment challenges remain. Increased used of
nonmyeloablative conditioning and improved methods
of stem cell procurement have led to a shortening of the
preengraftment neutropenic period in transplant
patients [1-3]. As a result, immune suppression associ-
ated with graft-versus-host disease (GVHD) and the
ever-frequent use of central venous catheters become
the predominant risk factors for severe, often recur-
ring, and sometimes lethal infections in the transplant
population [3-5]. The development of new treatment
options to combat opportunistic these infections in
this patient population remains a major direction of
transplant research in the 21st century.Bacterial Infections and New Antimicrobials
The continuing emergence of antibiotic-resistant
bacterial pathogens in transplant patients prevents
the use of ‘‘standard regimens’’ applicable to all febrile
patients. Gram-negative bacilli such as Pseudomonas
aeruginosa [6,7], multidrug resistant Escherichia coli,
and Stenotrophomonas maltophilia, as well as Gram-
positive cocci such as methicillin-resistant Staphylococ-
cus aureus and penicillin-resistant viridans Streptococci
and vancomycin-resistant enterococci have increased
in prevalence at many institutions [3,8]. Physicians
caring for neutropenic or chronically immunosup-
pressed transplant recipients with GVHD must keep
informed about new advances in antimicrobial therapyDepartment of Infectious Diseases, Infection Control and
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6/j.bbmt.2008.10.005and new patterns of resistance. The development of
broad-spectrum antibacterials such b-lactams, quino-
lones, aminoglycosides, glucopeptides has been 1 of
the major success stories in supportive care of cancer
as severe, frequently lethal bacterial infections, espe-
cially infections caused by Gram-negative rods have
decreased as in the last 3 decades [9,10]. Unfortunately,
resistance to available antibiotics has been increasing at
an alarming rate. At the same time, the pipeline for new
antibacterial agents has diminished because antibiotic
development is perceived as not cost-effective by indus-
try [11]. Several factors have been identified as contrib-
utors to this epidemic, including prolonged and
inappropriate use of antibiotics (especially as prophy-
laxis), greater severity of underlying malignant diseases
with prolonged immune dysfunction, and lapses in
infection control. As initial use of inadequate therapies
has been shown to be an independent predictor for in-
creased mortality [7,12-17], careful knowledge of the
local epidemiology, judicious use of the ‘‘big guns’’ in
the contexts of a careful stewardship program, and
investment in effective control practices are all impor-
tant components for prolonging the utility of existing
antimicrobial options [18,19]. Unfortunately, broad-
spectrum antibiotics required for appropriate empiric
therapy in transplant patients (carbapenems, third- to
fourth-generation cephaloporins, and fluoroquinones)
have been associated with the highest cumulative risks
for selection of Gram-negative resistant pathogens
(Figure 1) [20]. Once resistance develops, older antimi-
crobials once discarded because of concerns of nephro-
toxicity and neurotoxicity such as the polymyxins, may
be required for control of the infection [21]. Conse-
quently, there is a continuing need for new antimicrobial
agents in the clinical arena, especially for the treatment
of MDR Pseudomonas aeuriginosa, Acinetobacter baumanii,
Stenotrophomonas maltophilia, and ESBL-producing en-
teric Gram-negative rods.
Resistance rates among Gram-positive pathogens
have skyrocketed over the last decade. Data from the
National Nosocomial Infection Surveillance (NNIS)
program has demonstrated that the mean rates of
vancomycin-resistant enterococci (VRE) and methicil-
lin-resistant Staphylococcus aureus (MRSA) in 2003
increased 12% and 11%, respectively, over the last
5 years [22,23]. Approximately 60% of S. aureus
Figure 1. Cumulative risk for emergence of Gram-negative resistant organisms by treatment and duration of hospitalization. Adapted fromHarbarth S,
Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin
Infect Dis. 2001;33:1462-1468.
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to methicillin. In addition, MRSA is now found be-
yond healthcare facilities, causing an epidemic of com-
munity-associated MRSA (CA-MRSA) infections [23].
Not surprisingly, CA-MRSA strains carrying SCC mec
type IV and the Panton-Valentine leukocidin are now
invading hospitals and are associated with increased
mortality [24].
Although vancomycin has long been considered
the mainstay antibiotic for staphylococcal infections
and empiric coverage of organisms classically associ-
ated with catheter-related bloodstream infection,
a growing body of evidence suggests that this ‘‘work-
horse’’ antibiotic is quickly loosing ground for
MRSA infections. Of particular concern, many treat-
ment failures have now been well documented when
the vancomycin MICs are at the upper limit of the
susceptibility breakpoints (ie, MICs of 1-2 mg/mL)
[25]. Although, higher vancomycin doses (ie, to target
trough 15-20 mg/mL) can somewhat restore vancomy-
cin activity against these marginally susceptible
isolates, higher doses of this glycopeptides are associ-
ated with increased risk of nephrotoxicity [26]. As
a result, newer agents approved for treatment of
MRSA infection, such as daptomycin and linezolid,
are increasingly being used for empiric therapy.
Unfortunately, these agents may have limited efficacy
for treating certain types of infections (eg, daptomycin
for pulmonary infections; linezolid for bloodstream
infections) and resistance to these agents is already
being observed [27].
Prolonged, broad-spectrum antibiotic use may
also be associated with the development of Clostridium
difficile-associated diarrhea (CDAD). Acquisition of C.
difficile is a multifactorial process that involved antibi-
otic use, exposure to the organism, and a variety of host
factors including age, immune status, and gastric acid
suppression [28]. Although the prevalence of CDAD
has not been extensively investigated in the cancer
populations, CDAD has been reported in 7% of acuteleukemia patients receiving myelosuppressive chemo-
therapy, with 8.2% of patients developing severe
enterocolitis [29]. In recent years, large outbreaks of
CDAD in North America and Europe have been
attributed to the emergence of a fluoroquinolone-
resistant epidemic strain termed ‘‘North American
PFGE type 1 or NAP1,’’ that encodes genes for binary
toxin and has a genetic alteration that results in
increased in vitro toxin production [30]. The genetic
variant strain has been associated with increased sever-
ity of C. difficile infection, a high relapse rate, and
significant mortality[31], emphasizing the importance
of care attention to antimicrobial selection and dura-
tion of therapy to reduce the patient risk for acquiring
this virulent strains. Although any antibiotic can
be associated with the development of CDAD, the
highest antibiotic risks are seen with clindamycin,
third-generation cephalosporins, broad-spectrum
penicillins, and fluoroquinolones [32].
Although studies conducted in the 1980s and 1990s
demonstrated that oral metronidazole and oral vanco-
mycin were equally effective for treatment of CDAD
[33-35], the emergence of the epidemic strain has coin-
cided with reports of high rates of treatment failure met-
ronidazole treatment of CDAD [36,37]. In addition,
several recent studies have reported delayed treatment
responses for metronidazole compared to vancomycin
for severe CDAD [38,39]. Consequently, many experts
now recommend starting with oral vancomycin cap-
sules 125-500 mg 4 times daily in any patient with Ileus,
white blood cells (WBC).20,000, sepsis, renal failure,
pseudomembranous colitis, or anasarca [40].
Table 1 depicts our rather modest portfolio
antibacterial pipeline. The portfolio consists primarily
of 3 new lipoglycopeptides active against MRSA and
vancomycin-resistant enterococci, a new carbapenem
and cephalosporins, a more potent trimethoprim
derivative (iclaprim), and a novel antiviral for cytomeg-
alovirus (CMV). Of these new antibiotics, doripenem
and ceftobiprole the only new agents with activity
Table 1. New Antimicrobials Recently Introduced or in Phase II Testing
Class Agent Spectrum Unique Properties
Lipoglycopeptides Dalbavancin Oritavancin
Telavancin
Gram-positive including MRSA and VRE Intravenous only.Dalbavancin has a mean
terminal half- life of 149 to 300 hours in
human subjects
Carbapenem Doripenem Gram negative Similar spectrum to meropenem
Cephalosporin Ceftaroline Ceftobiprole Gram + (including MRSA) and Gram negative Ceftibiprole lacks activity against ESBL
organisms. Ceftaroline lacks activity against
nonferementers, including P. aeruginosa
Dihydrofolate reductase
inhibitor
Iclaprim Similar to spectrum to trimethoprim with
enhanced MRSA activity
Available in intravenous and oral formualtions
Antivrial
(benzimidazole riboside)
Maribavir Cytomegalovirus, no coverage
of HSV, or VZV
No appreciable hematologic or organ toxicities
MRSA indicates methicillin-resistant Staphylococcus aureus;VZV, varicella zoster virus; HSV, herpes simplex virus; VRE, vancomycin-resistant enterococci.
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unlikely to have major advantages over currently avail-
able third- to fourth-gerneation cephalosporin’s
(ceftazidime, cefepime) or antipseudomonal carbape-
nems (imipenem, meropenem).
Dalbavancin is a semisynthetic lipoglycopeptide
that inhibits cell wall synthesis with activity against
MRSA. The unique feature of this antimicrobial is its
prolonged half-life (6-10 days), which allows for
once-weekly dosing. Dalbavancin (1000 mg given
intravenously on day 1 and 500 mg given intravenously
on day 8) was shown to be as effective as linezolid for the
treatment of complicated skin and soft tissue infections
(SSTI) in a randomized, double-blind trial [41]. Dalba-
vancin was superior to vancomycin (87% versus 50%;
P\ .05) in a open-label, phase II trial of the treatment
of catheter-related bloodstream infections [42]. The
most common adverse events included nausea and
diarrhea or constipation; however, dalbavancin may
also be associated with hypotension, hypokalemia, and
increases in alanine aminotransferase and aspartate ami-
notransferase levels measured in liver function tests [43]
Telavancin is another a dual-mechanism of action
semisynthetic lipoglycopeptide that inhibits cell wall
synthesis and disruption of membrane barrier function
[44]. The drug has a half-life of 7–9 h, which allows
once-daily dosing at 7.5–10 mg/kg/day. Because of
the dual mechanism of the drug, telavancin exhibits
more rapid bactericidal activity than vancomycin
against many bacterial pathogens, including MRSA.
It is currently under investigation for the treatment
of SSTIs, nosocomial pneumonia, and uncomplicated
bacteremia because of S. aureus [44]. In published trials
to date, the efficacy of telavancin was similar to that of
standard therapy in early trials [45-47]. Unpublished
results from phase III clinical trials indicate that
televancin the clinical cure and eradication rates were
higher than those associated with vancomycin, partic-
ularly in patients infected with MRSA [27]. Adverse
events reported to date include nausea, taste distur-
bance, and insomnia.
Oritavancin is the third semisynthetic glycopep-
tide that is in late stages of clinical development. The
mechanism of action of this drug involves disruptionof transmembrane potential, allowing the drug to
maintain activity against vancomycin-resistant strains
of staphylococci and enterococci [48]. Oritavancin
has a long half-life (100 hours), which will probably
allow for dosing every 48 hours. Oritvancin is cur-
rently being studied for the treatment of SSTIs, cath-
eter-related bloodstream infections, and nosocomial
pneumonia [49]. Initial results from phase II SSTIs
showed noninferiority of oritavancin to vancomycin
and cephalexin. Adverse events associated with orita-
vantin have been mild, and included include headache,
nausea, and sleep disorders.
Ceftobiprole medocaril is an extended-spectrum,
fifth-generation cephalosporin with activity against
methicillin-resistant Staphylococcus spp., vancomycin-
resistant Staphylococcus aureus, penicillin-resistant
Streptococcus pneumoniae, vancomycin-resistant Entero-
coccus faecalis, Enterobacteriaceae, and Pseudomonas
aeruginosa. The enhaced activity of these cephalospo-
rin’s against Gram positive is due the the enhanced
binding of the drug to penicillin-binding protein 2a,
a peptidoglycan transpeptidase that confers beta-
lactam resistance in S. aureua isolates harboring the
themecA gene [50,51]. The cephalosporin lacks activity
against extended-spectrum b-lactamase (ESBL), pro-
ducing Enterobacteriaceae and Enterococcus faecium.
Ceftobiprole may have similar activity to cefepime
and ceftazidime against P. aeruginosa and limited activ-
ity against Acinetobacter baumannii, Burkholderia cepacia,
and Stenotrophomonas maltophilia. Preliminary data sug-
gest that ceftobiprole may be effective with a 1-hour
infusion of 500 mg every 12 hours for Gram-positive
infections and 500 mg every 8 hours with a 2-hour
infusion for polymicrobial infections [52].
Similar to ceftabiprole, ceftaroline is new broad-
spectrum cephalosporin that has activity that en-
compasses many community- and hospital-acquired
pathogens, including MRSA, multidrug-resistant
S. pneumoniae (including multidrug-resistant isolates)
and common (non-ESBL-producing) Gram-negative
bacteria. However, ceftralonine lacks clinically useful
antipseudomonal activity; therefore, its primary role
will likely be in the treatment of complicated SSTIs
including those caused by MRSA.
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of trimethoprim, which has shown to be a potent,
extended-spectrum in vitro activity against Gram-
positive bacteria, including methicillin-resistant
Staphylococcus aureus, vancomycin-intermediate, and
vancomycin-resistant S. aureus, and macrolide-, qui-
nolone-, and trimethoprim-resistant strains [53]. In
addition, iclaprim has demonstrated activity against
Streptococcus pneumoniae including penicillin-, erythro-
mycin-, levofloxacin-, and trimethoprim/sulfamethox-
azole-resistant strains [54-57]. Iclaprim also has potent
activity against Legionella and Pneumonocystis carinii
pneumonia [54,57]. Iclaprim may represent a useful
alternative to traditional trimethoprim/sulfamethoxa-
zole in patients who cannot tolerate sulfa drugs.
Although iclaprim has been shown to be effective for
complicated skin and skin structure infections, further
studies are underway examining the efficacy of this
compound for respiratory tract infections.Viral Infections and New Antivirals
For a number of years, bacterial and fungal infec-
tions were the major cause of infection in cancer
patients. With the development of more aggressive
therapies for high-risk leukemia, the widespread use
of stem cell transplantation (HSCT), and expanding
use of purine antimetabolites and monoclonal
antibodies that suppress cell-mediated immunity, viral
infections have emerged as a prominent challenge in
the supportive care of high-risk patients [58]. Some
DNA viruses such as herpes simplex, varicella, and cy-
tomegalovirus, have been long recognized as a cause of
serious infections in patients with hematologic malig-
nancies [59]. The highly immunosuppressive regimens
used for stem cell transplantation (SCT) have created
a population of recipients who are at risk for a variety
of other serious viral infections such as adenoviruses,
polyoma virus, and community respiratory viruses,
which are major contributors to deterioration of
pulmonary function in SCT recipients [60-62]. Fortu-
nately, rapid diagnostic techniques and effective thera-
pies have become available that make it possible to
manage some of these infections successfully.
For decades, management of CMV infection in
patients relied on the administration of ganciclovir or
foscarnet in patients with pneumonitis or positive shell
vial culture, when infection was relatively advanced
and mortality rates are high [63]. The development
of preemptive treatment strategies based on early
detection CMV replication or shedding through the
quantitative PCR or the pp65 antigen considerably
improved patient outcomes [64]. Increased prophylac-
tic and preemptive use of antivirals, however, may
be contributing to increases in ganciclovir- and foscar-
net-resistant CMV infections in many transplant
centers. However, antiviral therapies for CMV haveremained relatively unchanged over the last 2 decades,
and the toxicities associated with ganciclovir, foscar-
net, or cidofovir therapy can be formidable. The inves-
tigational agent maribavir, a benzimidazole riboside
that has no appreciable hematologic, renal or hepatic
toxicities and is the first new CMV therapy to reach
later stage clinical trials in many years, appears to
active against ganciclovir-resistant CMV strains [65].
Unfortunately, mutations in the UL97 kinase gene
imparting crossresistance between ganciclovir and
maribavir have already been reported before the even
before maribavir has come into clinical use [66].
Unlike foscarnet, maribavir does not have activity
against herpes simplex virus or varicella virus, so con-
comitant acyclovir may be required in profoundly
immunosuppressed patients.
Clinical Approach in the Transplant Recipient
with a Presumed Bacterial or Viral Infection
Given the inability of these hosts to mount an
adequate inflammatory response, the classic signs and
symptoms of infection even the presence of fever,
may be minimal or absent. A meticulous and focused
physical examination and take notice of every minor
or subtle sign and symptom of infection is important.
A focused physical examination should be repeated
daily if the symptoms persist and always include exam-
ination of the skin, skin folds, genitalia, anal area,
sinuses, oropharynx, and the site of intravenous lines.
Similarly, the lack of an adequate inflammatory
response renders some laboratory tests unreliable.
Concomitant blood cultures obtained from peripheral
veins and/or a catheter also should be performed.
A differential time to positively of $120 minutes
between cultures drawn through the catheter and
from a peripheral vein is highly specific for catheter-
related bacteremia.
Needless to say, an efficient clinical microbiology
laboratory that provides reliable antibiograms is of
paramount importance for the selection of appropriate
antibiotics. A number of recent studies have suggested
high-resolution chest computed tomography may
indicate early signs of invasive mold infection, such
as the halo sign, even in patients with a normal chest
radiograph. As previously stated, clinicians should be
aware of the predominant pathogens and an antibio-
gram that depicts the in vitro susceptibility patterns
of the most prevalent pathogens in their own institu-
tion to select an efficient initial empirical therapy.
FUTURE PERSPECTIVES
Many challenges lay ahead and a number of impor-
tant future objectives that need to be met. First, the
immunopathogenesis of bacterial and fungal infections
is poorly understood and the contribution of in vitro re-
sistance to suboptimal efficacy of modern antiinfectives
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and logistically difficult. These infections are often
complex, heterogeneous, frequently multifocal, and
therefore management is difficult. Many factors other
than antiinfective therapy per se, such as failure to
recover from neutropenia, delayed therapy, and the
site of involvement, affect outcome and have not been
clearly controlled in many studies. The very low rate
of autopsies in cancer patients who die with fever or
a lung infiltrate further compounds the uncertainty
about the real value of new drugs and diagnostic
methods to management. One example is worthwhile
to mention: combination therapy or adjunct immune
therapy for recalcitrant bacterial and or fungal infec-
tions—both conceptually appealing strategies. To
date, no clinical studies have convincingly determined
whether antibacterial or antifungal combinations are
more beneficial than therapy using monotherapy, espe-
cially in high-risk patients with cancer. The sequence
and timing of these combinations are important areas
of future investigation. On the drug front, new, effec-
tive antibacterials and antivirals must be developed to
combat resistant pathogens. On the patient evaluation
front, researchers must refine existing models of risk
stratification to reliably identify low- and high-risk
patients; create algorithms for the most appropriate
treatment with in select patients; and introduce new,
nonculture-based modalities for the early detection of
infections, especially those caused by fungi. By doing
so, the hope will be to replace empirical therapy with
pathogen-specific preemptive therapy in the near fu-
ture. Furthermore, the immunopathogenesis of infec-
tions in cancer patients and improvements in immune
augmentation are all important goals.ACKNOWLEDGMENTS
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